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Background: This paper introduces a tool for streamlining data integration in rehabilitation science, the Centralized Open-Access Rehabilitation database for Stroke (SCOAR),
which allows researchers to quickly visualize relationships among variables, efficiently
share data, generate hypotheses, and enhance clinical trial design.
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Methods: Bibliographic databases were searched according to inclusion criteria leaving
2,892 titles that were further screened to 514 manuscripts to be screened by full text,
leaving 215 randomized controlled trials (RCTs) in the database (489 independent groups
representing 12,847 patients). Demographic, methodological, and statistical data were
extracted by independent coders and entered into SCOAR.
results: Trial data came from 114 locations in 27 different countries and represented
patients with a wide range of ages, 62 year [41; 85] [shown as median (range)] and
at various stages of recovery following their stroke, 141 days [1; 3372]. There was
considerable variation in the dose of therapy that patients received, 20 h [0; 221], over
interventions of different durations, 28 days [10; 365]. There was also a lack of common
data elements (CDEs) across trials, but this lack of CDEs was most pronounced for
baseline assessments of patient impairment and severity of stroke.
conclusion: Data integration across hundreds of RCTs allows clinicians and researchers
to quickly visualize data from the history of the field and lays the foundation for making
SCOAR a living database to which researchers can upload new data as trial results are
published. SCOAR is a useful tool for clinicians and researchers that will facilitate data
visualization, data sharing, the finding of relevant past studies, and the design of clinical
trials by enabling more accurate and comprehensive power analyses. Furthermore,
these data speak to the need for CDEs specific to stroke rehabilitation in randomized
controlled trials.
PrOsPerO 2014:CRD42014009010
Keywords: stroke, rehabilitation, informatics
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INTRODUCTION

MATERIALS AND METHODS

The information architecture in rehabilitation science is poor
(1). For example, randomized controlled trials (RCTs) are the
basic “unit” of information that guide clinical practice. Yet when
clinicians and scientists want to ask a very basic question of these
data, they are published: (1) across a wide spectrum of journals
and formats that often have limited access (e.g., payment required
for access); (2) embedded potentially in text, tables, figures, or
even supplemental materials; and (3) with very few common data
elements (CDEs) reported across studies (2, 3). Thus, despite the
tremendous time and financial burdens associated with even a
single RCT, the resultant data lack a consistent structure. This
lack of structure is an unnecessary barrier to integration in
future scientific and clinical practice. Efforts to streamline data
integration should increase the transparency and visibility of
comprehensive bodies of evidence, rather than a single study,
to better inform clinically relevant questions such as, “How do
therapy outcomes change with increased time in therapy?” or
“How variable are outcomes, historically, for specific parameters
of therapy?”
We now introduce one such tool for streamlining data integration: the Centralized Open-Access Rehabilitation database for
Stroke (SCOAR). In short, SCOAR is a central repository for summary statistics from RCTs. SCOAR currently contains data from
a systematic review and extraction of papers from 1981 to early
2014 (described in detail below), but the goal of SCOAR is much
bigger: to create a “living” database where new data can be added
as clinical trials are completed. Imposing such an architecture (4)
on clinical trial data would allow basic and clinical scientists to
(1) quickly and easily visualize relationships among variables, (2)
efficiently share data, (3) generate hypotheses based on noticeable patterns or even “gaps” in the current data, (4) search the
current literature from the data up (rather than key-terms down),
and (5) improve clinical trial design through more accurate and
comprehensive power analyses.
Generally speaking, the goal of SCOAR is to improve the
design of future clinical trials by giving researchers fast and
easy access to the historical range of effect-sizes, based on
thousands of stroke patients who received therapies of different
types, different doses, at different times, and were measured on
different outcomes. From our perspective, the effort associated
with the design, implementation, and dissemination of randomized clinical trials deserves an information architecture that
supports and increases their visibility. In the current paper, we
(1) explain the systematic search and data extraction that led to
the creation of SCOAR; (2) present summary statistics for the
major variables in SCOAR, including the geographical reach,
to understand how SCOAR data represent research in stroke
rehabilitation; and (3) based on the lack of CDEs we find across
many variables, we argue for a consistent set of CDEs in rehabilitation trials (CDEs to describe participants, methodology,
and outcomes). SCOAR lays the foundation for an information
architecture that captures some of the complex and multivariate
nature of neurorehabilitation. Most importantly, this information architecture is scalable, making it easy to add new data as
new trials are published.

Systematic Review

Frontiers in Neurology | www.frontiersin.org

A systematic search was undertaken in May 2014 (full details in
PROSPERO 2014:CRD42014009010) using the following databases: MEDLINE, EMBASE, Cochrane CENTRAL, CochraneCDSR, and CINAHL. Outside references were also incorporated
from previous reviews (5, 6) (Figure 1). After removing duplicates,
2,892 remaining titles and abstracts were screened by independent coders (two pairs of trained graduate students) based on the
following inclusion/exclusion criteria (7):

Population

Human adults with stroke, >18 years of age, with a motor
impairment as a result of stroke. Any etiology was included (e.g.,
ischemic, hemorrhagic, sub-arachnoid hemorrhage) provided
that the study identified patients as having a stroke or cerebrovascular vascular accident. Groups with mixed neurological impairments (e.g., patients had either stroke or TBI) were excluded. (In
the RCTs we found, the majority of groups were characterized
as having first-ever unilateral strokes, without other neurological
conditions, but these were not criteria for inclusion.)

Intervention

Any physical or occupational therapy interventions that required
active movement on the part of the participant were included.
RCTs that used stimulation techniques were allowed (e.g., FES,
TMS, tDCS) if combined with active movement. Studies with
strictly pharmaceutical interventions (e.g., to treat spasticity)
were excluded.

Control

All studies had to be RCTs and studies were required to explicitly
state random assignment to groups. The condition nominally
identified as “control” by the authors was coded as control, or
if a group received “conventional care,” “routine therapy,” or
“standard care” without being specifically named as control, it was
assumed that this was the control condition. All other conditions
were labeled as “experimental.”

Outcome

Only empirically validated assessments of impairment or functional motor capacity (i.e., activity limitations) administered by
the clinician were taken as outcomes (e.g., no self-report measures, no neuro-imaging measures, no study-specific kinematic/
kinetic measures). Note that studies could include these other
types of measures, but only measures of impairment or function
were extracted for inclusion in the database at this time.
If there was disagreement between the coders, the first
author (Keith R. Lohse) provided a tie-breaking vote on inclusion or led discussion until agreement was reached. The same
PICO inclusion/exclusion criteria were also applied to the full
text review. During the full text review, the authors systematically extracted data from the manuscripts (described below in
Section “Data Extraction”). During the extraction, concerns
emerged regarding how to consider statistically related
data within SCOAR. In other words, SCOAR is designed to
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FIGURE 1 | PRISMA Flow diagram showing the manuscript screening process. At the eligibility assessment, manuscripts were excluded if the population
was not stroke, there was no random assignment to at least two different groups, if the intervention did not meet our population, intervention, control, and outcome
criteria, if the outcomes were not a clinical measure of function/impairment, if no full text of manuscript was available (e.g., restricted access or the text only existed
in abstract form), if the data in the manuscript came from a larger study/reanalysis of a study that was already in the database, if the manuscript was a review,
commentary, or a trial protocol (rather than a trial itself), or if it was not clear how the study related to an existing study in the database (i.e., possibly the same
patients being analyzed twice; coded as “other”).

Data Extraction

longitudinally track groups over time (viz., from baseline
assessment, to terminal assessment, to the last long-term
follow-up) and, therefore, studies with long-term follow-up
data, subsets of data, or re-analyzed data published in separate
manuscripts presented a unique challenge. To maintain independence of the data for statistical analysis, any given group
of patients should only appear in the SCOAR database once.
Thus, subsets and re-analyses were excluded (n = 8) or if the
relationship between manuscripts was unclear (n = 5), those
studies were excluded as well. However, if a paper published a
long-term follow-up or reported usable outcome measures in
a separate manuscript (n = 8), then these data were grouped
together in the SCOAR database [e.g., Ref. (8–11)], such that
independence between groups is maintained. As shown in
Figure 1, there were a number of studies for which the full
text could not be obtained (n = 49), or even if the full text was
available, there was no available English translation (n = 9).
(At present, no effort has been made to translate these nonEnglish texts, but with adequate translation, the data from
these studies may be eligible for inclusion following review.)
In total, SCOAR has summary statistics from 12,847 patients
in 489 independent groups (as of 2016-03-31).

Frontiers in Neurology | www.frontiersin.org

Separate from the pairs of graduate students who screened by title
and abstract, three authors (Keith R. Lohse, Sydney Y. Schaefer,
Adam C. Raikes) extracted data by hand from electronic copies
of manuscripts using a standardized data extraction form. These
extracted values were then entered by hand into a spreadsheet.
Discrepancies between extractors were discussed until consensus
was reached. A copy of the data extraction form is listed in Data
Sheet S1 in Supplementary Material and an explanation of all
current SCOAR variables is included in the data dictionary, Data
Sheet S2 in Supplementary Material.
One author (Keith R. Lohse) extracted outcome data for
either the primary outcome or the first usable outcome, when
no primary outcome was stated or the primary outcome was not
usable. As per the PICO criteria, a usable outcome measure was
defined as an assessment given by a therapist that was a clinical
measure of motor impairment and/or function. Two authors
( Sydney Y. Schaefer, Adam C. Raikes) also reviewed all of the
articles to extract all additional data related to the Fugl–Meyer
Assessment (FMA, upper-extremity portion, a measure of upper
limb impairment) and gait speed (including the 10-m walk test,
or variations thereof, a measure of walking function). This second
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all effect-size calculations were for a Cohen’s d as described in
Borenstein et al. (21).

set of outcomes was extracted regardless of whether the FMA
or gait speed measure was stated as a primary outcome. FMA
and gait speed measures were chosen for this second extraction
because they were the most commonly reported measures for
those two domains in previous work (12).
In extracting these data, the relevant outcome data were
often clearly presented. For instance, baseline means and SDs
were consistently reported in the text (i.e., the pre-intervention
assessment, reported in 93 and 83% of cases), whereas terminal
means (i.e., the most immediate post-intervention assessment;
calculable for 93% of cases) sometimes had to be calculated
by the data extractors from reported change scores (12% of
calculable cases). Additionally, terminal SDs (calculable for
72% of cases) were sometimes estimated by the data extractors
from figures or reported confidence intervals (3% of calculable
cases).
Other data were often not reported in the text and, therefore, had to be estimated by the data extractors. For instance,
the time scheduled for therapy was typically estimated from
written descriptions (e.g., “1 h per day, 5 days per week for
4 weeks” = 20 h of scheduled therapy). An estimate of the time
scheduled for therapy was calculable in 74% of cases. Although
some studies reported repetitions of movements (13, 14) or
active time in therapy (15, 16), the most common metric was
the time scheduled for therapy. Although time scheduled for
therapy is likely to be a poor indicator of the actual amount of
therapy received (17), it is positively correlated with the amount
of therapy received and was the most common metric reported
across trials. Constraint-induced movement therapies (18,
19) or other “forced-use” therapies (20) were problematic for
estimating the time scheduled for therapy because they often
do not specify the amount of time actually spent in constraint
or forced-use. In line with previous work (6), we calculated
time under constraint in three different ways: (1) counting
100% of constraint time as time in therapy, (2) counting 50%
of constraint time as time in therapy, and (3) counting 0% of
constraint time as time in therapy. The 50% time calculation is
preferred because it has the most plausible assumptions (i.e.,
some, but not all, of constraint time is spent using the affected
extremity), but all three calculations are available to researchers
in the database. We further note that some constraint studies
reported constraint for a “percentage of waking hours,” and
these percentages were converted to hours based on 16 waking
hours per day.

d=

(1)

where spooled is the between-person SD pooled between the two
different time points to create a single estimate of the betweenperson variance.
spooled =

(n1 − 1) s12 + (n2 − 1) s22
(n1 + n2 − 2 )

(2)

Thus, s12 and s22 refer to the variance at the baseline and the
terminal assessment, respectively. In 28% of the total cases, the
variance was not estimable at the terminal assessment. However,
in 16% of the total cases the baseline SD was available and used
in the calculation of d when the terminal SD was not available. In
fewer cases (1% of total cases), the variance at baseline was zero
(e.g., all participants had a Functional Ambulation Category of
zero due to a floor effect in the outcome measure). In those cases,
the terminal SD was used in the calculation of d.
Finally, given the wide range of the effect-sizes and sample
sizes we observed in the data, we transformed these effect-sizes
from Cohen’s d to Hedges’ g. Cohen’s d is biased to overestimate
the underlying effect-size in small samples whereas Hedges’ g is a
more conservative and unbiased calculation of the effect-size in
which the d value is reduced proportional to the sample size (21).
Subtraction in the effect-size calculations was arranged such that
positive values in SCOAR always reflect improvement relative to
baseline.
Although the default effect-sizes in SCOAR represent the
normalized improvement within a group over time, we should
point out that SCOAR also contains the sample size, mean, and
SD for all groups at the baseline, terminal, and follow-up assessment (if applicable). Having these descriptive statistics for each
group at each time point allows researchers to readily calculate
between-group effect sizes if those effects are more relevant to
their research question. Thus, by extracting the sample size,
mean, and SD at each time point, SCOAR allows researchers to
calculate outcomes in three different ways: (1) a standardized
effect-size showing change within a group over time (the default
SCOAR effect-size), (2) a standardized effect-size showing the
difference between groups at a single point in time, or (3) the
original “raw” units of the outcome measure. Although using
original units precludes combining different outcomes into a
single analysis, this is a sensible option when restricting outcomes to a single type (i.e., measures of gait speed can all be
expressed in terms of meters per second, so there is no need to
normalize).

Estimation of Within-Group Effect Size

Compared to effect-size calculations in other rehabilitation metaanalyses (5, 6), the default effect-size in SCOAR represents the
change within groups over time rather than a difference between
groups at a specific time point. Calculating a standardized
effect-size for within-group change is important, because these
effect-sizes allow for the greatest flexibility in integrating changes
across studies using the most data [i.e., each group’s improvement
(or decrement) is normalized to their baseline at the beginning
of the intervention]. Calculation of these within-group changes
creates some unique challenges for meta-analysis (see below), but

Frontiers in Neurology | www.frontiersin.org

y1 − y2
spooled

Estimation of the Correlation between
Time Points and Effect-Size Variance

In order to conduct quantitative meta-analyses with these data, we
also need to calculate the variance of the individual effect-sizes.
For statistically dependent “within-subject” data, the correlation
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between time points, r, is required for an accurate estimation of
effect-size variance, Vd (21).
 1 d2 
Vd =  +  2 (1 − r )
 n 2n 

available from https://github.com/keithlohse/SCOAR. (Note that
SCOAR is licensed under a Creative Commons AttributionShareAlike 4.0 International License by Keith R. Lohse.)
As shown in Table 1, the data in SCOAR are representative of
a wide range of patients (in terms of day-post stroke and age) and
different types of interventions (in terms of sample size, duration
of the intervention, and dose of therapy given over the intervention). An important point to note are the different methods used
for tracking the dose of therapy patients received. Consistent with
our previous work (6), the most common metric for tracking dose
was the hours of scheduled therapy. The best measures of dose are
the time actively spent doing therapy (19, 35) (which was more
commonly reported in gait therapies) or the actual repetitions of
therapy exercises (14, 36) (which was more commonly reported
in trials using robotic assistive devices).

(3)

The correlation between baseline and terminal (or followup) scores was never reported in any of the included RCTs. We
were, however, able to estimate the correlation between baseline
and terminal assessments from studies that provided either (A)
individual patient data or (B) SDs of the baseline, terminal, and
baseline-to-terminal change scores (21). In this subset of studies (13, 22–34), we observed that the median correlation was
r = 0.87, IQR = (0.70, 0.93) and the minimum correlation was
r = 0.28 between baseline and terminal assessments. As such,
we calculated effect-size variance based on the conservative
assumption that r = 0.5 for all studies (which generally creates
larger estimates of variance in the data, widening our confidence
intervals). This estimated correlation is, however, an easy value
for researchers to manipulate within SCOAR and recalculate
their own effect-size variances. Thus, the default effect-size
variance in SCOAR is calculated based on r = 0.5, which we
consider to be a conservative estimate, but researchers can easily
recalculate effect-size variances by scaling this correlation up
or down.

Geographical Distribution of Studies

As shown in Figure 2, trials in the SCOAR database come from
a wide range of countries. The location of a trial was estimated
based on the contact information for the corresponding author.
Note that multiple studies may be represented by each dot (if
trials were conducted at the same location), so we refer readers
to the interactive version of this figure1 where they can see the
number of trials, number of groups, and the references for each
location. Overall, trials came from 114 locations in 27 different
countries. From this wide range of trial locations, it does not
appear that SCOAR is geographically biased relative to the larger
population of stroke rehabilitation trials. The extent to which the
population of trials might be biased, however, is an important

RESULTS
Descriptive statistics across the 489 independent groups of participants currently in the database are listed in Table 1. The full
database (as of 2016-03-31), the data dictionary, a full reference
list all trials, and the Creative Commons license for SCOAR are

1

http://tinyurl.com/SCOAR-regions

TABLE 1 | Demographic statistics for the studies included in SCOAR.
Variable

Mean (SD)

Median (IQR)

Min; Max

Groups with
missing values

Mean patient age (years)
Mean days post stroke (days)
Duration of intervention (days)

62.6 (6.7)
509 (652)
45 (39)

62.4 (57.3; 67.3)
141 (31; 840)
28 (28; 42)

41.30; 85.20
1; 3,372
10; 365

12
22
20

Estimated Time Scheduled for Therapy (h)
Max time calculation
50% time calculation
Min time calculation

34.2 (45.3)
29.9 (31.6)
25.5 (24.5)

20.0 (10.0; 36.1)
20.0 (10.0; 36.0)
20.0 (10.0; 32.0)

0.0; 280.0
0.0; 220.7
0.0; 220.7

129
129
129

Method for Tracking Dose of Therapy – N (% out of 489)
Hours scheduled
Time in therapy
Active time
Repetitions
Groups Reporting ITT Analysis
N per Group at baseline calculation
N per group at terminal calculation
N per Group at follow-up calculation
Time from baseline to follow-up (days)
Coded as experimental groups
Coded as control groups

307 (63%)
26 (5%)
37 (8%)
20 (4%)
158 (32%)
26 (26)
25 (25)
29 (29)
178 (137)
285 (58%)
204 (42%)

18 (11; 31)
17 (10; 30)
19 (2; 34)
180 (88; 206)

4; 165
4; 165
4; 165
31; 1,098

0
6
215
231

N per group refers to the number of participants whose data were used in the calculation of the mean and the SD at each time point, not necessarily the number of participants
enrolled in/actively participating in the study at that time point (depending on the analytical method used by the authors). Time in days and N per group are rounded to the nearest
integer. ITT = intention to treat.

Frontiers in Neurology | www.frontiersin.org
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FIGURE 2 | Geographical distribution of studies in the SCOAR database based on the contact information for the corresponding author. Each dot
represents one city in a given region, but there may be multiple studies from a single city (e.g., there are three different RCTs and six independent groups, from
Chicago, IL, USA). An interactive version of this figure is also available from http://tinyurl.com/SCOAR-regions; generated using Tableau 9.0 (Tableau Software;
Seattle, WA, USA).

question. As seen in Figure 2, there is a dearth of trials for regions
such as South America, Africa, central Asia, and eastern Europe.

TABLE 2 | Most common data elements for baseline measures in the 489
independent groups included in SCOAR.
Measure

Common Data Elements for Baseline
Assessment and Initial Severity

Across the 489 independent groups of participants, there was a
wide range of data elements, but unfortunately there were relatively few CDEs reported across the different studies. This lack
of CDEs was especially pronounced for variables measuring the
baseline severity of stroke or patient impairment. For example,
data describing cognitive status with the Mini-Mental Status
Exam (MMSE) were reported for only 152 groups in some form
(31% of cases). A mean or median MMSE score was given for 82
(17%) of these groups, whereas 70 (14%) of these groups only
reported some cut-off/critical MMSE value in their inclusion/
exclusion criteria. The MMSE example was not unusual, however,
and was actually the most common CDE for baseline assessment.
For a list of the most common baseline assessments and their
prevalence (see Table 2).
This lack of CDEs (or at least under-reporting of CDEs) is
undoubtedly a major barrier to data integration and meta-analysis,
especially for ostensibly common baseline assessments, such as
the FIM or NIHSS. We should clarify that it is possible that authors
were using these assessments/screening criteria in the actual trial,
but they may not have been reporting these measures and we can
only extract and analyze the descriptive statistics based on the
published information. Indeed, many inclusion/exclusion criteria

Frontiers in Neurology | www.frontiersin.org

Number of groups
with mean/median
value reported

Number of groups
with cut-off stated
in I/E criteria only

Not
reported

MMSE
(or modified) (37)

82 (17%)

70 (14%)

337 (69%)

Ashworth (or
modified) (38)

63 (13%)

25 (5%)

401 (82%)

Barthel
(or modified) (39)

68 (14%)

2 (<1%)

419 (86%)

FAC (40)

46 (9%)

10 (2%)

433 (89%)

FIM (41)

47 (10%)

2 (<1%)

440 (90%)

Brunnstrom
stages (42)

24 (5%)

20 (4%)

445 (91%)

Motricity Index (43)

28 (6%)

7 (1%)

454 (93%)

NIHSS (44)

34 (7%)

0 (0%)

455 (93%)

Berg Balance
Scale (45)

34 (7%)

0 (0%)

455 (93%)

I/E, inclusion/exclusion criteria, MMSE, Mini-Mental Status Exam, FAC, Functional
Ambulation Category, FIM, Functional Independence Measure, NIHSS, National
Institutes of Health Stroke Scale.

were vague, with authors often reporting “no excessive spasticity”
(implying perhaps the Ashworth scale was used), “no cognitive/
communicative impairments” (implying the MMSE may have
been used), or “no severe depression” (implying perhaps the Beck
Depression Inventory or the Center for Epidemiological Studies
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depression scale were used). Without more complete reporting,
we have no way of knowing which measures were collected and
how participants were evaluated. This presents a major gap in
stroke rehabilitation knowledge (1).

compared are very different. At the moment, the under-describing
of control therapies allows for very different interventions to all
be categorized as “standard care” in different trials.

Classification and Common Data
Elements in Outcome Measures

Classification and Description
of Therapy Types

There is a very wide range of outcome measures in SCOAR
(n = 78 discrete outcome names) (3). Despite this multiplicity,
all of the SCOAR outcomes are measures of impairment and/or
motor function. Thus, these outcomes could be analyzed together
in order to get a broad view of motor recovery outcomes. We
have, however, built in several default filters in SCOAR to help
researchers group common outcomes more quickly. The first filter
is the “outcome_extremity” variable in the database, which codes
outcomes based on the involvement of the upper-extremity (ue)
and lower-extremity (le). Variables that do not cleanly fit into one
of these categories (e.g., the Barthel Index or other activities of
daily living scales) are left blank. Within the ue and le outcomes,
we further subdivide outcomes with a second-level filter. Secondlevel filter codes for the upper-extremity in SCOAR include the
Fugl–Meyer Assessment (fma), Action Research Arm Test (arat),
and Wolf Motor Function Test (wmft). Second-level filter codes
for the lower-extremity in SCOAR include measures of walking
speed (including the 10-m walk test and variants thereof), walking
endurance (including the 6 min walk test and variants thereof)
and balance (which includes the Timed Up and Go Test and the
Berg Balance Scale). The number of outcomes of each type is
shown in Figure 3.
Naturally, some researchers may disagree with the filters/
groupings, we have created for the defaults in the SCOAR database.
As such, outcomes are also coded without a filter, using the name
of the outcomes from the original study (the “outcome_name”
variable in the database). In many cases, this unfiltered option
will be appealing because it offers the user the greatest control
over what information to pool together. However, if the user does
not care which subscale of the FMA is being used (e.g., the ue
total subscale, the wrist-hand subscale, or the shoulder-elbow

An unexpected difficulty in the construction of the SCOAR
database was in how to categorize/classify different therapeutic
interventions. Ideally, researchers could use the SCOAR database
to look at effect-sizes as a function of therapy-type or ask other
meta-scientific questions about therapy types. Indeed, we were
able to extract a short phrase or informative description of the
therapy for almost all of the experimental groups (e.g., “CIMT,”
“intensive progressive treadmill training”; these descriptions are
listed under the “group_desc” variable in the SCOAR database),
consistent with TIDieR Criteria (46, 47). For control groups,
however, this proved much more difficult, with many descriptions being simply “conventional physiotherapy,” “standard
care,” or “routine care.” We are currently pursuing text-mining
approaches to better quantify the nature of therapy provided in
control-arms of trials. In the included RCTs, however, control
groups were under-described compared to experimental groups
(48). Looking strictly at the Methods sections of papers, for
instance, control groups only had a mean (SD) of 155 (112)
words and 0.82 (1.9) references dedicated to their description.
Experimental groups, conversely, had 271 (159) words and 1.77
(3.4) references dedicated to their description. Example control
group descriptions are:
“All participants received standard rehabilitation,
including 40 minutes each of physiotherapy and occupational therapy, given once per day, five days per week
for six weeks, by the rehabilitation team. [… sentence
about experimental group omitted…] The control group
had visits and discussions of 20 minutes at least three
times per week instead.” (49)
“All participants received the site’s conventional inpatient rehabilitation. They also performed a daily 10-m
walk (or shorter distance walk until 10 m was feasible)
as part of a physical therapy session.” (50)
“All participants received a duration-matched intervention for 90 to 105 minutes/day, 5 days/week for 4 weeks.
The CT group received an intensive therapist-administered control therapy matched in duration with the
RT groups. Occupational therapy techniques used in
the treatment protocols included neurodevelopmental
treatment, muscle strengthening, fine-motor training,
and functional task training.” (14)
Adequate descriptions of control therapies are critical, not
only because the SCOAR database spans three decades and
“routine” therapy has changed considerably over that period, but
also because it is impossible to compare the efficacy of a treatment across trials if the control groups to which the treatment is
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FIGURE 3 | The frequency of different outcome measures for the
upper-extremity (ue, n = 212), lower-extremity (le, n = 443), and
subscales of those two codes. Complex whole body assessments that
did not fit into one of these two categories were unclassified (n = 144).
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subscale) then the second-level filter fma would be appropriate
to use. Similarly, walking speed was measured in many different
ways across the different studies. For example, walking speed
was measured over 10, 8, or even 4.2 m, and at both self-selected
velocity and maximal effort, but if the user is not concerned about
such differences in these outcomes, then the second-level filter
speed would be appropriate to use.
The wide variation in outcomes measures means that if a
researcher wants to focus on a single outcome, it would greatly
reduce the amount of data that can contribute to any single
analysis. As with baseline CDEs, the reporting of so many different outcome measures with so few common outcome measures
imposes severe limitations on hypothesis generation and data
exploration. From the SCOAR database, there is a strong argument for consistent CDEs describing participant demographics,
study methodology, and clinical outcomes. Panels of experts
would be required to determine exactly what these CDEs should
be (e.g., What are the best UE/LE outcome measures with respect
to their sensitivity and clinical application?). While the exact battery of CDEs needs to be determined, it is clear that creating a
comprehensive set of rehabilitation specific CDEs would enable
researchers to ask innovative questions of existing data, bringing
the results of hundreds of trials to bear on clinically relevant topics with unprecedented precision and statistical power.

with “group-level” statistics more generally. One limitation is
completeness; the data currently in SCOAR represent two waves
of data extraction: the first wave extracted the first primary or
secondary outcome measure that met our inclusion criteria while
the second wave extracted any assessment based on the FMA or
a measure of gait speed/endurance. This creates a representative,
but not exhaustive extraction of all of the outcome measures
used across the various studies. Currently, we are extracting the
remaining outcomes from these RCTs, regardless of whether or
not this outcome was primary or secondary. Once this third wave
of data extraction is complete, SCOAR will contain all of the available summary statistics for any clinical measure of impairment or
function used in these studies. We have also re-implemented our
systematic search to update the database through 2016 and are
in the process of extracting demographic, methodological, and
statistical information from those studies.
Even as the evidence base in SCOAR expands, there is a
major concern with the lack of CDEs in both outcome and
baseline measures. From an information architecture perspective,
reporting multiple outcomes per trial poses a unique problem.
For instance, self-selected gait speed and maximal gait speed or
various subscales of the FMA could all be reported in the same
RCT. In SCOAR, this can be resolved by creating separate rows
for each outcome, which is a relatively simple problem of scale.
For the researcher, however, it is not always clear which measure
is best or if one should average across multiple related measures,
reflecting a more complicated problem of ontology (i.e., what
are the fundamental constructs in rehabilitation and how do
we measure them?) (53–55). This lack of CDEs is indicative of
a larger problem for rehabilitation science as a field: researchers
need to think critically about which measures to collect/analyze
in order to reduce the risk of false positives (56–58) and (ideally)
develop a set of common measures for key constructs (1, 2, 59)
that would allow for greater data integration across trials.
Similarly, a major concern across trials was in the way that
therapies were reported. For control therapies in particular, the
descriptions of the control interventions were vague and underreported in comparison to experimental interventions. Control
therapies had approximately half of the words dedicated to their
description as experimental therapies. This lack of detail might
be acceptable if control therapies had sufficient references to support them (e.g., references to standard operating procedures or
other published guidelines). However, this does not seem to be
the case, as control interventions had about half of the number
of references in their descriptions compared to experimental
interventions, and less than one reference on average. (It should
be noted that these word/reference counts were based only on the
text in the Methods sections of the original papers.)
For both control and experimental therapies, there is also a
concern about how the dose of therapy is reported across trials.
At the moment, the only consistently reported measure was time
scheduled for therapy and we stress that this measure gives only
a rough indication of the amount of physical practice actually
performed during therapy. It would be preferable to develop a
system where the type, intensity, and volume of physical practice could be tracked for individual patients and consistently

Data-Driven Searches and Novel Filters

A major advantage of organizing trial data in a central repository
is that it can complement traditional bibliographic databases, such
as PubMed or EMBASE. Traditional bibliographic tools assist
authors in finding data from the top-down. That is, researchers
arrive at data via well-designed searches using key terms, author
names, medical subject headings, etc. By contrast, data-driven
searches allow authors to find resources from the bottom-up. That
is, SCOAR allows researchers to plot the relationships between
variables and then click on large, outlying, or otherwise interesting data-points to obtain more information about that trial, such
as patient demographics, type of intervention, and the reference
for the published manuscript. For example, see http://tinyurl.
com/SCOAR-datasearch.
In addition to these data driven searches, SCOAR enables
researchers to constrain their searches by filters that are not
available in bibliographic databases. For instance, a researcher
could filter SCOAR to find only those trials that have used the
ARAT as an outcome, in patients < 70 years old, and with sample
sizes greater than 30. [Indeed, there are currently two studies in
SCOAR that meet these specific criteria (51, 52).] Having these
key variables describing participant demographics, research
methodology, and clinical outcomes in an easily searchable
database makes SCOAR a very useful compliment to existing
bibliographic databases.

DISCUSSION
While SCOAR is a large step forward for data integration in stroke
rehabilitation research, there are limitations associated with the
database in its current form and limitations in using a database
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FIGURE 4 | Schematic showing the transformation of data from an unstructured format (i.e., separate texts, tables, and figures, often behind
paywalls) to a structured format (i.e., SCOAR database) and our long-term goal of making SCOAR accessible to researchers through the internet.
This webpage would allow users to interact with the data (generating both statistical and graphical outputs) and allow researchers to upload new data (following a
validation process) as new trials are published.

reported across studies. The development of such a system would
be a large undertaking, but if there was a consistent mechanism/
taxonomy for quantifying what exercises were done, at what
intensity, and at what volume during therapy, this would help
overcome problems with under-describing therapies. Such a
taxonomy, if validated, would also improve our understanding
of what the key “active-ingredients” actually are in physical and
occupational therapy (60).
Another limitation of having a database of summary statistics,
rather than individual patient data, is the “resolution” of the data
available to researchers. Obviously this resolution would be finer
if individual data were available for each patient in each trial (for
example, see the Virtual International Stroke Trials Archive),2
but having a database of individual patient data raises privacy
concerns that limit open-access to the database and (potentially)
the type of variables that can be included in the database (i.e., data
that may jeopardize anonymity). Thus, SCOAR is ultimately more
“share-able” than individual patient data and potentially easier to
maintain.
Finally, as shown in Figure 4, the long-term goal of SCOAR is
to create a “living” database where researchers can add new trials
to the database through the internet. We are currently working to
develop a website with a graphical user interface that would exist
on top of SCOAR, allowing researchers to visualize relationships
between different variables in the database and/or download
the raw data from SCOAR so that they can work with it offline.

2

Furthermore, a major goal of this website is to allow researchers to
upload new data as trials are published. By creating fillable forms
that fit our data structure, we can make it very easy for researchers
(e.g., the corresponding authors) to upload demographic information about their participants, methodological data about their
intervention, and statistical information about their outcomes.
This uploading would be validated by one of the SCOAR study
personnel working with the author to ensure the quality/accuracy
of the new data before it is officially added to SCOAR.

CONCLUSION
The SCOAR database currently integrates demographic, methodological, and statistical data from 215 RCTs (representing 12,847
patients) that allows researchers to quickly visualize relationships
between variables in motor rehabilitation for adults with stroke.
Integrating data from 30+ years of published studies is certainly
not trivial, but establishing this information architecture makes
it easy to scale the database as new trials are published. In our
own research, we are using SCOAR to analyze how the dose
and timing of therapy interact to affect therapy outcomes, and
by combing data from SCOAR with text-mining approaches we
are exploring what “conventional” or “standard” therapy actually
means in the context of RCTs (48). The open-access nature of
SCOAR will help researchers and clinicians to (1) visualize
relationships among variables based on the history of the field,
(2) efficiently share data between trials, (3) generate hypotheses
by allowing for exploratory meta-analyses, (4) search the current
literature by complimenting existing bibliographic databases, and

http://www.vista.gla.ac.uk/
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